Search results for Carlumab

Carlumab Biosimilar – Anti-CCL2, MCP-1, MCAF, SCYA2 mAb – Research Grade, ProteoGenix, PX-TA1252

Description of Carlumab Biosimilar - Anti-CCL2, MCP-1, MCAF, SCYA2 mAb - Research Grade General information on Anti-CCL2/MCP-1/MCAF/SCYA2[Homo sapiens] (Carlumab) Monoclonal Antibody Carlumab has beeninvestigated for the treatment of Cancer and more specifically Prostate Cancer.

Carlumab, Abbexa, abx831207

Carlumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting CCL2/MCP-1/MCAF/SCYA2, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications. Carlumab has been used in trials studying the treatment of Cancer and Prostate Cancer.

Carlumab ELISA Kit, ProteoGenix, KPTX180

Description of Carlumab ELISA Kit Title: Understanding Carlumab ELISA Kit: A Revolutionary Tool for Detecting and Measuring Antibodies Against a Promising Therapeutic Target Introduction: Carlumab, also known as CNTO 888, is a novel human monoclonal antibody that has shown promising results in clinical trials for the treatment of various autoimmune and inflammatory diseases. As with any therapeutic target, it is crucial to have reliable methods for detecting and measuring antibodies against Carlumab. This is where the Carlumab ELISA Kit comes into play. In this article, we will delve into the structure, activity, and application of this revolutionary kit in the field of antibody research. Structure of Carlumab: Carlumab is a fully human monoclonal antibody that specifically targets and binds to the cytokine interleukin-6 (IL-6). It is composed of two heavy chains and two light chains, with a molecular weight of approximately 150 kDa. The antibody has a unique structure that allows it to bind to IL-6 with high affinity, thereby inhibiting its activity. Activity of Carlumab: IL-6 is a pro-inflammatory cytokine that plays a crucial role in the pathogenesis of various diseases such as rheumatoid arthritis, multiple myeloma, and Castleman’s disease. By binding to IL-6, Carlumab blocks its interaction with its receptor and prevents the downstream signaling cascade, thereby reducing inflammation and disease progression. This makes Carlumab a promising therapeutic target for the treatment of these diseases. Application of Carlumab ELISA Kit: The Carlumab ELISA Kit is a valuable tool for researchers and clinicians to detect and measure antibodies against Carlumab in serum or plasma samples. This kit utilizes the sandwich ELISA technique, where the capture antibody is coated on a microplate and the detection antibody is conjugated with an enzyme. When a sample containing Carlumab antibodies is added to the microplate, the antibodies bind to the capture antibody, forming a sandwich complex. The addition of a substrate then produces a color change, which is measured and quantified using a spectrophotometer. The Carlumab ELISA Kit has several advantages over other methods of antibody detection. It is highly sensitive, with a detection limit of 0.1 ng/mL, allowing for the detection of even low levels of antibodies. It is also specific, as it only detects antibodies against Carlumab and not other antibodies. This specificity is crucial in differentiating between patients who have been treated with Carlumab and those who have not. Additionally, this kit is easy to use, with a simple protocol and a short incubation time of only 2 hours. Conclusion: In conclusion, the Carlumab ELISA Kit is a powerful tool for detecting and measuring antibodies against Carlumab. Its high sensitivity, specificity, and ease of use make it an essential tool for researchers and clinicians working with this promising therapeutic target. With the increasing use of Carlumab in clinical trials and potential approval for use in various diseases, the Carlumab ELISA Kit will continue to play a crucial role in antibody research and drug development.

Carlumab ELISA Kit, Abbexa, abx395069

Carlumab ELISA Kit is a quantitative ELISA kit for detection of Carlumab.Carlumab, developed by Janssen Biotech, is a recombinant human IgG1 monoclonal antibody targeting CC chemokine ligand 2 (CCL2). The recombinant protein has been developed for the treatment of cancer and prostate cancer, and has also been studied in systemic sclerosis, atherosclerosis, diabetic nephropathy, liver fibrosis, and type 2 diabetes. In the beginning, phage display technology was used to confirm the high affinity between Carlumab and CCL2, which provided a basis for future clinical trials. In 2013, Carlumab was used to treat metastatic castrated prostate cancer and solid tumors. The anti-tumor activity of Carlumab was preliminarily determined through the study of its safety, tolerance, pharmacokinetics-pharmacodynamics and anti-tumor activity. Subsequently, some studies have evaluated the safety and efficacy of Carlumab in the treatment of (IPF) with idiopathic pulmonary fibrosis, but the results are not satisfactory. Due to the limited success rate of clinical trials, carlumab was discontinued in 2012.

Carlumab Biosimilar - Research Grade, ichor.bio, ICH5143

Detects human CCL2

Research Grade Carlumab (HY280016), abinScience, HY280016